why choose us

First received: September 20, 2022

Clinical Trial: Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Study Status: Completed

Recruit Status: RECRUITING

Condition: Myeloid Diseases

Study Type: INTERVENTIONAL


Official Title: A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases

Brief Summary: Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890 in patients with myeloid diseases.The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS) and lower risk chronic myelomonocytic…

Read more